Literature DB >> 18514883

Erysipelothrix rhusiopathiae infection of a total knee arthroplasty an occupational hazard.

Emily A Traer1, Mark R Williams, Jon N Keenan.   

Abstract

A 76-year-old man with a medical history of rheumatoid arthritis, lupus intersititial nephritis, and steroid therapy was found at first-stage revision total knee arthroplasty to have Erysipelothrix rhusiopathiae (a zoonotic pathogen normally associated with pigs and fish) infection of the arthroplasty. He had a history of potential occupational exposure to the organism. On literature review, we found only 3 other case reports of E rhusiopathiae linked to septic arthritis in humans. This unique case of an infected joint arthroplasty further illustrates the pathogenicity of E rhusiopathiae in humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18514883     DOI: 10.1016/j.arth.2007.02.011

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  4 in total

1.  Clinical manifestations, associated diseases, diagnosis, and treatment of human infections caused by Erysipelothrix rhusiopathiae: a systematic review.

Authors:  Mosayeb Rostamian; Donya Rahmati; Alisha Akya
Journal:  Germs       Date:  2022-03-31

Review 2.  Septic arthritis caused by Erysipelothrix rhusiopathiae in a prosthetic knee joint.

Authors:  Laurent Hocqueloux; Didier Marc Poisson; Simon Sunder; Sébastien Guilbert; Thierry Prazuck
Journal:  J Clin Microbiol       Date:  2009-11-18       Impact factor: 5.948

3.  A child with Erysipelothrix arthritis-beware of the little known.

Authors:  Chiranjay Mukhopadhyay; Hitesh Shah; K E Vandana; Frenil Munim; Sandeep Vijayan
Journal:  Asian Pac J Trop Biomed       Date:  2012-06

4.  Empyema in spinal canal in thoracic region, abscesses in paravertebral space, spondylitis: in clinical course of zoonosis Erysipelothrix rhusiopathiae.

Authors:  Jarosław Andrychowski; Piotr Jasielski; Tomasz Netczuk; Zbigniew Czernicki
Journal:  Eur Spine J       Date:  2012-04-17       Impact factor: 3.134

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.